Fox Run Management, L.L.C. Arcutis Biotherapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $526 Million
- Q4 2024
A detailed history of Fox Run Management, L.L.C. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 16,946 shares of ARQT stock, worth $247,750. This represents 0.04% of its overall portfolio holdings.
Number of Shares
16,946
Previous 19,330
12.33%
Holding current value
$247,750
Previous $179,000
31.84%
% of portfolio
0.04%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
218Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Jennison Associates LLC12.3MShares$180 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$167 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$160 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$128 Million7.34% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$126 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $880M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...